Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.

GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide

Hegedüs, Laszlo, Moses, Alan C., Zdravkovic, Milan, Le Thi, Tu, Daniels, Gilbert H. · 2011 · The Journal of Clinical Endocrinology & Metabolism

Abstract

BACKGROUND: Serum calcitonin (CT) is a well-accepted marker of C-cell proliferation, particularly in medullary thyroid carcinoma. Chronic glucagon-like peptide-1 (GLP-1) receptor agonist administration in rodents has been associated with increased serum CT levels and C-cell tumor formation. There are no longitudinal studies measuring CT in humans without medullary thyroid carcinoma or a family history of medullary thyroid carcinoma and no published studies on the effect of GLP-1 receptor agonists on human serum CT concentrations. AIM: The aim of the study was to determine serum CT response over time to the GLP-1 receptor agonist liraglutide in subjects with type 2 diabetes mellitus or nondiabetic obese subjects. METHODS: Unstimulated serum CT concentrations were measured at 3-month intervals for no more than 2 yr in a series of trials in over 5000 subjects receiving liraglutide or control therapy. RESULTS: Basal mean CT concentrations were at the low end of normal range in all treatment groups and remained low throughout the trials. At 2 yr, estimated geometric mean values were no greater than 1.0 ng/liter, well below upper normal ranges for males and females. Proportions of subjects whose CT levels increased above a clinically relevant cutoff of 20 ng/liter were very low in all groups. There was no consistent dose or time-dependent relationship and no consistent difference between treatment groups. CONCLUSIONS: These data do not support an effect of GLP-1 receptor activation on serum CT levels in humans and suggest that findings previously reported in rodents may not apply to humans. However, the long-term consequences of GLP-1 receptor agonist treatment are a subject of further studies.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2010-2318

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

See all 194

Metadata

Authors
Hegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H.
Affiliations
  • Department of Endocrinology (L.H.), Odense University Hospital, 5000 Odense, Denmark;
  • Novo Nordisk Inc. (A.C.M.), Princeton, New Jersey 08540;
  • Novo Nordisk (Denmark) (DK)
  • Novo Nordisk A/S (M.Z., T.L.T.), 2880 Bagsværd, Denmark;
  • Harvard University (US)
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2011-03-01
Volume
96
Issue
3
Pages
853-860
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2118710260
Cited by
194
References
25
Citations by year
2026: 6 · 2025: 4 · 2024: 8 · 2023: 9 · 2022: 4 · 2021: 3 · 2020: 5 · 2019: 14 · 2018: 7 · 2017: 7 · 2016: 10 · 2015: 26 · 2014: 19 · 2013: 28 · 2012: 29
FWCI
23.57
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
Funders
  • Novo Nordisk
  • Odense Universitetshospital
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
Keywords
calcitonin, liraglutide, GLP-1 receptor agonists, type 2 diabetes, obesity, medullary thyroid carcinoma, long-term safety, rodent-to-human extrapolation
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Adult, Calcitonin, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Receptors, Glucagon, Diabetes Complications, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide. https://app.cochat.ai/papers/10.1210/jc.2010-2318
The paper
Hegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011). GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2010-2318

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.